title: Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases.
abstract: This report describes two patients who developed jaundice within two weeks of receiving an amoxycillin-clavulanate potassium combination. Causes of jaundice, other than drug administration, were excluded. The patients' jaundice and clinical symptoms did not respond to stopping the drug. Ursodeoxycholic acid (750 mg/day) led to a prompt and sustained improvement in their hyperbilirubinaemia and symptoms such as pruritus and fatigue. These cases suggest that ursodeoxycholic acid may be an effective treatment for drug-associated cholestasis.
authors.affiliation: Second Department of Internal Medicine, Aristotelion University, Ippokration Hospital, Thessaloniki, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Katsinelos
authors.forename: T
authors.initials: T
authors.lastname: Vasiliadis
authors.forename: P
authors.initials: P
authors.lastname: Xiarchos
authors.forename: F
authors.initials: F
authors.lastname: Patakiouta
authors.forename: K
authors.initials: K
authors.lastname: Christodoulou
authors.forename: I
authors.initials: I
authors.lastname: Pilpilidis
authors.forename: N
authors.initials: N
authors.lastname: Eugenidis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000009:adverse effects*; D001706:Biopsy; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D011379:Prognosis; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
chemical_list: D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid; D019980:Amoxicillin-Potassium Clavulanate Combination